<DOC>
	<DOCNO>NCT01462253</DOCNO>
	<brief_summary>This multicentric , prospective pilot trial test Clofarabine-Cyclophosphamide combination treat refractory first bone marrow relapse adult ALL , achievement complete remission ( CR ) concurrent evaluation biological response ALL cell ( minimal residual disease , apoptosis DNA cell damage , pharmacogenomics ) .</brief_summary>
	<brief_title>Clofarabine-cyclophosphamide Salvage Therapy Refractory Relapsed Acute Lymphoblastic Leukemia ( ALL ) Adults</brief_title>
	<detailed_description>The propose treatment schedule consist combination Clofarabine plus Cyclophosphamide administer 5 consecutive day ( Treatment scheme ) . This open , nonrandomized prospective phase II trial aim evaluate ( 1 ) activity combination term CR rate . - STEP 1 . All eligible patient screened availability HLA-matched partially mismatch compatible HSCT donor , family relate - unrelated type ( early activation require ) , include cord blood haploidentical sibling . Moreover , pre-treatment investigation include collection storage patient ALL cell specific biological study relate sensitivity response study chemotherapeutic combination . - STEP 2 . Cycle 1 applied eligible patient enrollment criterion confirm . - STEP 3 . After cycle 1 , response evaluate . - STEP 4 . After remission induction cycle 1 , responsive patient ( CR PR , see definition ) could give cycle 2 , accord opinion responsible physician minimum intercycle interval 4 week day 1 cycle 1 . All NR patient declare study give second course study combination . The suggested treatment follow cycle 2 ( cycle 1 cycle 2 omit ) HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Signed write informed consent accord IGH/EU/GCP national local law . Age 1860 year . ALL B/Tprecursor phenotype refractory first line therapy . ALL B/Tprecursor phenotype 1st isolated bone marrow relapse , occur &lt; 24 month achievement first CR , chemotherapy hematopoietic stemcell transplantation ( HSCT ) define follow : * ≥ 5 % leukemic blast bone marrow attributable another cause ( e.g . marrow regeneration ) ; circulate blast bone marrow contain 520 % leukemic blast , repeat bone marrow perform least week later necessary confirm relapse . ECOG performance status 02 reversible ECOG 3 score follow intensive care complication . Adequate hepatic renal function , unless consider due organ leukemic involvement : Serum creatinine &lt; 1.5 mg/dl ; serum creatinine &gt; 1.5 mg/dl , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation Predicted GFR ( ml/min/1.73 m2 ) = 186 x ( Serum Creatinine ) 1.154 x ( age year ) 0.023 x ( 0.742 patient female ) , x ( 1.212 ) patient black . Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) . Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 2.5 x ULN . Alkaline phosphatase ≤ 2.5 x ULN . Prior exposure Clofarabine , primary refractory patient , Cyclophosphamide induction course . Patients relapse &gt; 24 month first CR . Philadelphia chromosomepositive ( Ph+ ) ALL . Diagnosis Burkitttype/BALL , B/Tlymphoblastic lymphoma &lt; 25 % bone marrow involvement . Concurrent isolated central nervous system ( CNS ) relapse . Preexisting , uncontrolled pathology cardiac disease ( congestive/ischemic , acute myocardial infarction within past 3 month , untreatable arrythmias , NYHA class III IV ) . Severe neurological psychiatric disorder impair patient 's ability understand sign inform consent , cope intend treatment plan . Active uncontrolled systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . HIV positive serology active hepatitis infection . Concurrent diagnosis active cancer require concurrent chemotherapy and/or radiotherapy , and/or life expectancy &lt; 1 year . Patients pregnant adult reproductive potential employ effective method birth control ( woman childbearing potential must negative serum pregnancy test within 48 hrs prior administration ClofarabineCyclophosphamide ) . Post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adult patient</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>clofarabine</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>refractory relapse acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
</DOC>